Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
General Outlook
In simple terms, Dermapharm Holding SE has 51.853 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.642% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.192%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.082%. This tells us they're good at keeping money after all costs.
Return on Investments
The company's asset efficiency, represented by a robust 0.044% return, is a testament to Dermapharm Holding SE's adeptness in optimizing resource deployment. Dermapharm Holding SE's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.174%. Furthermore, the proficiency of Dermapharm Holding SE in capital utilization is underscored by a remarkable 0.122% return on capital employed.
Stock Prices
Dermapharm Holding SE's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $41, while its low point bottomed out at $39.96. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Dermapharm Holding SE's stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”